ClearPoint Neuro, Inc. (CLPT) SEC Filings & Earnings Calls

Revenue guidance cut reflects shift in investment priorities away from traditional sales expansion, potentially delaying near-term revenue growth.

“We are adjusting our 2026 revenue guidance to between $48.0 - $52.0 million as our investment will be less focused on traditional sales expansion than previously planned.” · word for word

Biotech funding dependency

“constraints in the funding environment for these partners, whether due to capital markets conditions or changes in government research funding, could cause partners to delay, scale back or discontinue programs utilizing our products and services.” · word for word

Dependence on customer clinical trial success

“our ability to grow in this market is dependent on our ability to maintain and establish new relationships with pharmaceutical company customers, such customers' continuation of research and product development plans, such customers achieving success in completion of clinical trials and subsequent regulatory approvals of their drugs and biologics” · word for word

Macroeconomic uncertainty affecting customer spending

“Such changes in domestic and global macroeconomic conditions may lead to increased costs for our business. Additionally, these macroeconomic trends could adversely affect our customers, which could impact their willingness to spend on our products and services” · word for word

Cash burn remains high; operating cash flow negative $8M in Q1; expects cost synergies in H2 2026.

“use of $8.0 million in cash for operating activities ... expects cost synergies ... to contribute to a reduction in cash burn in the second half of 2026” · word for word

Related-party revenue concentration

“In 2024 and 2025, PTC made payments to us under the PTC Supply Agreement in the amount of $2.8 million and $2.9 million, respectively, representing approximately 16% and 15% of our biologics and drug delivery revenues for 2024 and 2025, respectively, or 9% and 8% of our total revenues for 2024 and 2025, respectively.” · word for word

Net loss trend

“Net Income (Loss) ($ thousands) ... 2025 (25,540) ... 2024 (18,914) ... 2023 (22,089)”

Operating Losses

“We have incurred net losses since our inception, which has resulted in a cumulative deficit at December 31, 2025 of $216.9 million.” · word for word

Near-Term Gross Margin Pressure from IRRA flow

“The IRRAS acquisition is expected to impact cost of revenue and reduce overall gross margins in the near term as IRRA flow currently operates at sub-scale production levels.” · word for word

Capital Equipment Revenue Decline

“Capital equipment and software revenue decreased 18% to $3.1 million for the year ended December 31, 2025.”

Partner Concentration Risk

“Our ability to grow in this market is dependent on our ability to maintain and establish new relationships with pharmaceutical company customers.” · word for word

Operating expenses increased 21% to $46.9M, outpacing revenue growth; integration costs and R&D spending may pressure profitability.

“Operating expenses were $46.9 million for the full year 2025, compared with $38.9 million for 2024, an increase of 21%.” · word for word

Preliminary results subject to revision upon audit completion.

“These preliminary unaudited financial results are management’s estimates, are subject to revision” · word for word

Internal reorganization may introduce operational or legal risks.

“internal reorganization involving the Company’s Swedish subsidiary, IRRAS AB, including the transfer of all equity interests of IRRAS USA, Inc. owned by IRRAS AB to the Company or its direct, wholly owned U.S. subsidiary in exchange for a subordinated intercompany note” · word for word

Integration risk and potential dilution from stock issuance.

“Issuance of 1.325M shares and earnout consideration based on net sales thresholds.”

Dependence on biopharma partner regulatory timelines

“Regulatory pathway and timelines for biopharma partners remain areas of active learning”

Going Concern Risk

“The Company has incurred net losses since its inception, which has resulted in a cumulative deficit at September 30, 2025 of $209.1 million.” · word for word

Customer Concentration

“One pharmaceutical customer accounted for 8% of total sales for each of the three and nine months ended September 30, 2025.”

Integration risk from acquisition

“Post-closing integration of IRRAS may pose operational challenges”

Share dilution from stock consideration

“1,325,000 shares of Company common stock issued as part of consideration” · word for word